Trade Emergent BioSolutions Inc. - EBS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.14 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 5.7 |
| Open | 5.63 |
| 1-Year Change | 127.02% |
| Day's Range | 5.52 - 5.66 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 21, 2025 | 5.65 | 0.06 | 1.07% | 5.59 | 5.70 | 5.52 |
| Mar 20, 2025 | 5.70 | -0.08 | -1.38% | 5.78 | 5.80 | 5.63 |
| Mar 19, 2025 | 5.78 | 0.11 | 1.94% | 5.67 | 5.90 | 5.66 |
| Mar 18, 2025 | 5.66 | 0.07 | 1.25% | 5.59 | 5.76 | 5.53 |
| Mar 17, 2025 | 5.74 | 0.14 | 2.50% | 5.60 | 5.86 | 5.56 |
| Mar 14, 2025 | 5.67 | 0.14 | 2.53% | 5.53 | 5.97 | 5.50 |
| Mar 13, 2025 | 5.45 | -0.57 | -9.47% | 6.02 | 6.15 | 5.44 |
| Mar 12, 2025 | 6.12 | 0.46 | 8.13% | 5.66 | 6.32 | 5.58 |
| Mar 11, 2025 | 5.50 | -0.03 | -0.54% | 5.53 | 5.62 | 5.23 |
| Mar 10, 2025 | 5.59 | 0.06 | 1.08% | 5.53 | 5.75 | 5.42 |
| Mar 7, 2025 | 5.72 | 0.01 | 0.18% | 5.71 | 5.98 | 5.56 |
| Mar 6, 2025 | 5.82 | 0.27 | 4.86% | 5.55 | 6.06 | 5.55 |
| Mar 5, 2025 | 5.77 | -0.46 | -7.38% | 6.23 | 6.43 | 5.74 |
| Mar 4, 2025 | 6.65 | 1.19 | 21.79% | 5.46 | 6.69 | 4.99 |
| Mar 3, 2025 | 6.82 | -0.72 | -9.55% | 7.54 | 7.54 | 6.72 |
| Feb 28, 2025 | 7.46 | 0.48 | 6.88% | 6.98 | 7.46 | 6.88 |
| Feb 27, 2025 | 7.03 | -0.26 | -3.57% | 7.29 | 7.46 | 7.02 |
| Feb 26, 2025 | 7.23 | 0.04 | 0.56% | 7.19 | 7.25 | 7.06 |
| Feb 25, 2025 | 7.18 | 0.15 | 2.13% | 7.03 | 7.25 | 6.92 |
| Feb 24, 2025 | 7.13 | -0.51 | -6.68% | 7.64 | 7.66 | 7.03 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Emergent BioSolutions Company profile
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. The company offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. It also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, the company offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4/7. Further, it offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, the company offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies/non-governmental organizations. Emergent BioSolutions Inc. has a development and manufacturing agreement with Novavax Inc. for coronavirus disease vaccine candidate. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.| Industry: | Pharmaceuticals (NEC) |
400 Professional Dr, Suite 400
GAITHERSBURG
MARYLAND 20879
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 700,000+ traders worldwide that chose to trade with Capital.com